✦ LIBER ✦

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

✍ Scribed by Roden, Michael; Weng, Jianping; Eilbracht, Jens; Delafont, Bruno; Kim, Gabriel; Woerle, Hans J; Broedl, Uli C

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and tolerability of sitagliptin

✍ Barzilai, Nir; Guo, Hua; Mahoney, Erin M.; Caporossi, Suzanne; Golm, Gregory T.; 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 259 KB

Comparison of empagliflozin and glimepir

✍ Ridderstråle, Martin (author);Andersen, Knut Robert (author);Zeller, Cordula (au 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 597 KB

Comparison of empagliflozin and glimepir

✍ Ridderstråle, Martin (author);Andersen, Knut Robert (author);Zeller, Cordula (au 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 597 KB

Low-dose interleukin 2 in patients with

✍ Hartemann, Agnès; Bensimon, Gilbert; Payan, Christine A; Jacqueminet, Sophie; Bo 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 251 KB

Efficacy and safety of sitagliptin monot

✍ Y. Iwamoto; N. Tajima; T. Kadowaki; K. Nonaka; T. Taniguchi; M. Nishii; J. C. Ar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

Efficacy and safety of canagliflozin com

✍ Lavalle-González, F. J.; Januszewicz, A.; Davidson, J.; Tong, C.; Qiu, R.; Canov 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 411 KB